Amylyx Pharmaceuticals develops drug candidates for endocrine conditions and neurodegenerative diseases, based in Cambridge, Massachusetts. AMLX reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints.
Prices, price targets and earnings estimates for AMLX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AMLX is in one of them and how their past AMLX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is a drug developer based in Cambridge, Massachusetts. The company is working on treatments for endocrine conditions and neurodegenerative diseases, many of them rare disorders with no approved treatments. Its lead candidate, avexitide, is being studied for a low blood sugar condition that can follow weight loss surgery. Its other programs target Wolfram syndrome, ALS and other rare diseases, with patients as the intended users of these treatments.
